Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
2016 · Journal of Clinical Oncology · 545 citations
https://doi.org/10.1200/jco.2016.67.1529
D
David R. Minor
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
116
Papers
11.5K
Citations
34
h-index
55
i10-index
David R. Minor is an academic researcher from W. L. Gore & Associates (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 34, co-authored 99 publications.
ORCID: 0000-0003-2186-2016Papers by this author
worksPhase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
2019 · Journal of Clinical Oncology · 173 citations
https://doi.org/10.1200/jco.19.01381
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
2014 · Annals of Surgical Oncology · 146 citations
https://doi.org/10.1245/s10434-014-4169-5
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
2011 · Melanoma Research · 112 citations
https://doi.org/10.1097/cmr.0b013e32834d3d88
Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients
2002 · Gynecologic Oncology · 94 citations
https://doi.org/10.1006/gyno.2002.6855
Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer
2017 · Gynecologic Oncology Reports · 12 citations
https://doi.org/10.1016/j.gore.2017.09.009
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat